Leland Shapiro
Concepts (185)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| alpha 1-Antitrypsin | 9 | 2015 | 104 | 1.280 |
Why?
| | alpha 1-Antitrypsin Deficiency | 3 | 2013 | 61 | 0.610 |
Why?
| | Shock, Septic | 1 | 2021 | 230 | 0.570 |
Why?
| | Meningitis, Cryptococcal | 3 | 2024 | 34 | 0.440 |
Why?
| | HIV Infections | 6 | 2024 | 3215 | 0.440 |
Why?
| | Sepsis | 1 | 2021 | 669 | 0.430 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2021 | 1224 | 0.330 |
Why?
| | Cryptococcosis | 2 | 2023 | 31 | 0.320 |
Why?
| | Cryptococcus | 2 | 2024 | 16 | 0.320 |
Why?
| | Interleukin-1beta | 3 | 2014 | 397 | 0.320 |
Why?
| | HIV-1 | 3 | 2015 | 913 | 0.280 |
Why?
| | Nitric Oxide | 2 | 2012 | 883 | 0.270 |
Why?
| | Interleukin-8 | 1 | 2009 | 268 | 0.260 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2009 | 253 | 0.260 |
Why?
| | Interferon-gamma | 3 | 2007 | 781 | 0.250 |
Why?
| | Mycobacterium Infections, Nontuberculous | 2 | 2012 | 339 | 0.240 |
Why?
| | Mycobacteriaceae | 1 | 2007 | 42 | 0.240 |
Why?
| | Receptors, CXCR4 | 1 | 2007 | 91 | 0.240 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2007 | 127 | 0.230 |
Why?
| | Interleukin-18 | 1 | 2007 | 234 | 0.220 |
Why?
| | Interleukin-10 | 1 | 2007 | 310 | 0.220 |
Why?
| | Cytomegalovirus | 1 | 2026 | 172 | 0.220 |
Why?
| | DNA, Viral | 1 | 2026 | 354 | 0.200 |
Why?
| | Cryptococcus neoformans | 1 | 2024 | 21 | 0.200 |
Why?
| | Cytomegalovirus Infections | 1 | 2026 | 206 | 0.200 |
Why?
| | Macrophages | 2 | 2012 | 1532 | 0.190 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2024 | 130 | 0.190 |
Why?
| | Anti-HIV Agents | 2 | 2007 | 914 | 0.180 |
Why?
| | Antigens, Fungal | 2 | 2024 | 28 | 0.170 |
Why?
| | Meta-Analysis as Topic | 1 | 2021 | 173 | 0.160 |
Why?
| | Cytokines | 4 | 2021 | 2081 | 0.160 |
Why?
| | Communicable Diseases, Emerging | 1 | 2020 | 39 | 0.150 |
Why?
| | Medical Errors | 1 | 2020 | 124 | 0.140 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2015 | 1150 | 0.120 |
Why?
| | Patient Safety | 1 | 2020 | 352 | 0.120 |
Why?
| | Islets of Langerhans Transplantation | 2 | 2008 | 72 | 0.120 |
Why?
| | Evidence-Based Medicine | 1 | 2020 | 731 | 0.120 |
Why?
| | Adult | 13 | 2026 | 41087 | 0.120 |
Why?
| | Low Density Lipoprotein Receptor-Related Protein-1 | 1 | 2015 | 12 | 0.110 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 1064 | 0.110 |
Why?
| | Middle Aged | 11 | 2026 | 36619 | 0.110 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 387 | 0.110 |
Why?
| | Coronavirus Infections | 1 | 2020 | 379 | 0.110 |
Why?
| | Research Design | 1 | 2021 | 1143 | 0.110 |
Why?
| | Humans | 22 | 2026 | 146342 | 0.110 |
Why?
| | Virus Activation | 1 | 2015 | 97 | 0.110 |
Why?
| | Hypocreales | 1 | 2014 | 8 | 0.100 |
Why?
| | Intraabdominal Infections | 1 | 2014 | 12 | 0.100 |
Why?
| | Virus Replication | 2 | 2021 | 526 | 0.100 |
Why?
| | Mycoses | 1 | 2014 | 87 | 0.100 |
Why?
| | Propensity Score | 2 | 2026 | 376 | 0.090 |
Why?
| | Myeloid Cells | 1 | 2014 | 149 | 0.090 |
Why?
| | RNA, Viral | 2 | 2021 | 693 | 0.090 |
Why?
| | NF-kappa B | 2 | 2015 | 674 | 0.090 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2012 | 162 | 0.090 |
Why?
| | Male | 14 | 2026 | 73396 | 0.090 |
Why?
| | Genetic Predisposition to Disease | 2 | 2013 | 2488 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1707 | 0.080 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2012 | 288 | 0.080 |
Why?
| | Dendritic Cells, Follicular | 1 | 2011 | 8 | 0.080 |
Why?
| | Female | 14 | 2026 | 79499 | 0.080 |
Why?
| | Monocytes | 1 | 2014 | 538 | 0.080 |
Why?
| | Phosphorylation | 2 | 2012 | 1724 | 0.080 |
Why?
| | Enzyme Activation | 1 | 2012 | 759 | 0.080 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2014 | 344 | 0.080 |
Why?
| | Emphysema | 1 | 2011 | 100 | 0.080 |
Why?
| | I-kappa B Proteins | 1 | 2011 | 75 | 0.080 |
Why?
| | Dendritic Cells | 1 | 2014 | 509 | 0.080 |
Why?
| | Epoprostenol | 1 | 2010 | 132 | 0.070 |
Why?
| | Blood Cells | 1 | 2009 | 38 | 0.070 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2623 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 846 | 0.070 |
Why?
| | Staphylococcus epidermidis | 1 | 2009 | 80 | 0.070 |
Why?
| | Risk Factors | 5 | 2024 | 10921 | 0.070 |
Why?
| | Physical Endurance | 1 | 2010 | 278 | 0.070 |
Why?
| | Islets of Langerhans | 1 | 2014 | 852 | 0.060 |
Why?
| | Aged | 7 | 2026 | 26432 | 0.060 |
Why?
| | Placebos | 1 | 2007 | 192 | 0.060 |
Why?
| | Cell Line | 1 | 2012 | 2814 | 0.060 |
Why?
| | Serine Proteinase Inhibitors | 1 | 2007 | 48 | 0.060 |
Why?
| | Immune Tolerance | 1 | 2008 | 386 | 0.060 |
Why?
| | Double-Blind Method | 2 | 2010 | 2070 | 0.060 |
Why?
| | Antihypertensive Agents | 1 | 2010 | 519 | 0.060 |
Why?
| | Transplantation Tolerance | 1 | 2005 | 41 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 3 | 2014 | 3930 | 0.060 |
Why?
| | Cells, Cultured | 2 | 2011 | 4118 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2011 | 2502 | 0.050 |
Why?
| | Case-Control Studies | 3 | 2018 | 3647 | 0.050 |
Why?
| | Apoptosis | 1 | 2011 | 2439 | 0.050 |
Why?
| | Phenotype | 2 | 2012 | 3206 | 0.050 |
Why?
| | History, 17th Century | 1 | 2020 | 14 | 0.040 |
Why?
| | Glucocorticoids | 1 | 2024 | 536 | 0.040 |
Why?
| | History, 21st Century | 1 | 2020 | 224 | 0.040 |
Why?
| | Mice | 3 | 2012 | 18297 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2010 | 5899 | 0.040 |
Why?
| | History, 20th Century | 1 | 2020 | 330 | 0.040 |
Why?
| | Hypertension, Pulmonary | 1 | 2010 | 1957 | 0.030 |
Why?
| | Hyponatremia | 1 | 2018 | 42 | 0.030 |
Why?
| | Mortality | 1 | 2020 | 375 | 0.030 |
Why?
| | Betacoronavirus | 1 | 2020 | 288 | 0.030 |
Why?
| | Prognosis | 1 | 2026 | 4351 | 0.030 |
Why?
| | Animals | 4 | 2012 | 38107 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2011 | 1298 | 0.030 |
Why?
| | Hospitals, University | 1 | 2016 | 178 | 0.030 |
Why?
| | Cohort Studies | 1 | 2007 | 6077 | 0.030 |
Why?
| | Inflammation | 1 | 2007 | 2919 | 0.030 |
Why?
| | Clathrin | 1 | 2015 | 26 | 0.030 |
Why?
| | Hearing Loss | 1 | 2018 | 177 | 0.030 |
Why?
| | Time Factors | 2 | 2021 | 7109 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 2016 | 201 | 0.030 |
Why?
| | Lysosomes | 1 | 2015 | 134 | 0.030 |
Why?
| | Cytosol | 1 | 2015 | 215 | 0.030 |
Why?
| | Prospective Studies | 1 | 2007 | 8123 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 486 | 0.030 |
Why?
| | Retrospective Studies | 2 | 2018 | 17438 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2018 | 561 | 0.030 |
Why?
| | Endocytosis | 1 | 2015 | 170 | 0.030 |
Why?
| | Microbiological Techniques | 1 | 2014 | 30 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1543 | 0.030 |
Why?
| | Endosomes | 1 | 2015 | 139 | 0.030 |
Why?
| | Young Adult | 3 | 2016 | 14330 | 0.020 |
Why?
| | Antifungal Agents | 1 | 2014 | 153 | 0.020 |
Why?
| | Toll-Like Receptors | 1 | 2014 | 193 | 0.020 |
Why?
| | Peritoneal Dialysis | 1 | 2014 | 100 | 0.020 |
Why?
| | Funnel Chest | 1 | 2012 | 31 | 0.020 |
Why?
| | Logistic Models | 1 | 2018 | 2126 | 0.020 |
Why?
| | Adipokines | 1 | 2012 | 56 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 2113 | 0.020 |
Why?
| | Gene Frequency | 1 | 2013 | 496 | 0.020 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 2011 | 48 | 0.020 |
Why?
| | PPAR alpha | 1 | 2011 | 56 | 0.020 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2011 | 57 | 0.020 |
Why?
| | Down-Regulation | 1 | 2014 | 614 | 0.020 |
Why?
| | Polyubiquitin | 1 | 2011 | 8 | 0.020 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2011 | 50 | 0.020 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2011 | 128 | 0.020 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2011 | 22 | 0.020 |
Why?
| | Lung Diseases | 1 | 2018 | 787 | 0.020 |
Why?
| | Disease Susceptibility | 1 | 2012 | 339 | 0.020 |
Why?
| | Caspase 3 | 1 | 2011 | 240 | 0.020 |
Why?
| | Prevalence | 1 | 2018 | 2861 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2011 | 158 | 0.020 |
Why?
| | Transcription Factor RelA | 1 | 2011 | 93 | 0.020 |
Why?
| | Ubiquitination | 1 | 2011 | 119 | 0.020 |
Why?
| | PPAR gamma | 1 | 2011 | 182 | 0.020 |
Why?
| | Smoke | 1 | 2011 | 149 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2011 | 245 | 0.020 |
Why?
| | Scoliosis | 1 | 2012 | 231 | 0.020 |
Why?
| | Hypertension | 1 | 2018 | 1272 | 0.020 |
Why?
| | RNA Interference | 1 | 2011 | 472 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2011 | 545 | 0.020 |
Why?
| | Pulmonary Alveoli | 1 | 2011 | 385 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2010 | 432 | 0.020 |
Why?
| | Adolescent | 3 | 2014 | 22557 | 0.020 |
Why?
| | Adipose Tissue | 1 | 2012 | 642 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 2014 | 589 | 0.020 |
Why?
| | Up-Regulation | 1 | 2011 | 841 | 0.020 |
Why?
| | Transplantation, Homologous | 1 | 2008 | 416 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2014 | 11821 | 0.020 |
Why?
| | Colorado | 1 | 2016 | 4595 | 0.010 |
Why?
| | Mice, Inbred C57BL | 2 | 2008 | 6034 | 0.010 |
Why?
| | Macrophage Inflammatory Proteins | 1 | 2005 | 11 | 0.010 |
Why?
| | Lymph Nodes | 1 | 2008 | 511 | 0.010 |
Why?
| | Chemokine CCL4 | 1 | 2005 | 31 | 0.010 |
Why?
| | Granulocytes | 1 | 2005 | 82 | 0.010 |
Why?
| | Chemokine CCL3 | 1 | 2005 | 26 | 0.010 |
Why?
| | Mice, Inbred DBA | 1 | 2005 | 186 | 0.010 |
Why?
| | Walking | 1 | 2010 | 546 | 0.010 |
Why?
| | Cell Movement | 1 | 2008 | 951 | 0.010 |
Why?
| | Body Mass Index | 1 | 2012 | 2458 | 0.010 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2005 | 365 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2016 | 8391 | 0.010 |
Why?
| | Child | 2 | 2014 | 22693 | 0.010 |
Why?
| | Rats | 1 | 2011 | 5586 | 0.010 |
Why?
| | Cell Line, Tumor | 1 | 2011 | 3545 | 0.010 |
Why?
| | Killer Cells, Natural | 1 | 2005 | 481 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2010 | 2921 | 0.010 |
Why?
| | Interleukin-1 | 1 | 2005 | 960 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2011 | 4580 | 0.010 |
Why?
| | Heart Failure | 1 | 2014 | 2329 | 0.010 |
Why?
| | United States | 1 | 2018 | 16136 | 0.010 |
Why?
| | Diabetes Mellitus | 1 | 2008 | 1101 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2008 | 2599 | 0.010 |
Why?
| | Biomarkers | 1 | 2010 | 4340 | 0.010 |
Why?
| | Exercise | 1 | 2010 | 2213 | 0.010 |
Why?
|
|
Shapiro's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|